Immunovant (IMVT) Short Interest Ratio & Short Volume $16.80 -0.01 (-0.04%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$16.80 +0.00 (+0.01%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunovant Short Interest DataImmunovant (IMVT) has a short interest of 19.92 million shares, representing 29.05% of the float (the number of shares available for trading by the public). This marks a -8.12% decrease in short interest from the previous month. The short interest ratio (days to cover) is 12.6, indicating that it would take 12.6 days of the average trading volume of 1.22 million shares to cover all short positions.Current Short Interest19,920,000 sharesPrevious Short Interest21,680,000 sharesChange Vs. Previous Month-8.12%Dollar Volume Sold Short$311.95 millionShort Interest Ratio12.6 Days to CoverLast Record DateJune 15, 2025Outstanding Shares170,920,000 sharesFloat Size68,570,000 sharesShort Percent of Float29.05%Today's Trading Volume511,903 sharesAverage Trading Volume1,218,103 sharesToday's Volume Vs. Average42% Short Selling Immunovant? Sign up to receive the latest short interest report for Immunovant and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMVT Short Interest Over TimeIMVT Days to Cover Over TimeIMVT Percentage of Float Shorted Over Time Immunovant Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/202519,920,000 shares $311.95 million -8.1%29.1%12.6 $15.66 5/31/202521,680,000 shares $322.38 million +1.3%31.6%12.5 $14.87 5/15/202521,400,000 shares $297.89 million +3.3%31.4%12.7 $13.92 4/30/202520,710,000 shares $334.47 million -0.6%30.4%11.7 $16.15 4/15/202520,830,000 shares $322.24 million +5.8%30.5%11.7 $15.47 3/31/202519,690,000 shares $336.50 million +24.6%28.9%11.6 $17.09 3/15/202515,800,000 shares $308.42 million +2.7%22.8%11 $19.52 2/28/202515,390,000 shares $317.03 million +4.1%22.2%13.3 $20.60 2/15/202514,790,000 shares $300.68 million +12.5%21.3%13.2 $20.33 1/31/202513,150,000 shares $285.88 million +2.5%19.2%11.7 $21.74 Get the Latest News and Ratings for IMVT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. 1/15/202512,830,000 shares $313.05 million +4.7%21.7%13.8 $24.40 12/31/202412,260,000 shares $303.68 million -2.9%19.7%14.6 $24.77 12/15/202412,630,000 shares $331.92 million -0.3%20.3%14.9 $26.28 11/30/202412,670,000 shares $357.29 million -2.7%20.4%15.2 $28.20 11/15/202413,020,000 shares $346.72 million -0.6%21.0%14.5 $26.63 10/31/202413,100,000 shares $383.31 million +1.3%21.1%15.6 $29.26 10/15/202412,930,000 shares $369.15 million +2.3%20.8%14.3 $28.55 9/30/202412,640,000 shares $360.37 million +1.4%20.4%13.1 $28.51 9/15/202412,460,000 shares $369.69 million +0.6%20.1%11.9 $29.67 8/31/202412,390,000 shares $382.85 million +1.3%20.0%11.9 $30.90 8/15/202412,230,000 shares $377.66 million +9.1%19.8%10.6 $30.88 7/31/202411,210,000 shares $325.87 million +10.1%18.1%9.8 $29.07 7/15/202410,180,000 shares $310.59 million +1.6%16.5%8.9 $30.51 6/30/202410,020,000 shares $264.53 million -1.1%16.0%8.8 $26.40 6/15/202410,130,000 shares $263.38 million +10.0%16.4%8.9 $26.00 5/31/20249,210,000 shares $233.84 million -0.9%15.0%7.8 $25.39 5/15/20249,290,000 shares $287.34 million +3.7%15.3%8.7 $30.93 4/30/20248,960,000 shares $245.86 million +5.3%14.8%7.9 $27.44 4/15/20248,510,000 shares $259.30 million -5.7%14.1%7.4 $30.47 3/31/20249,020,000 shares $291.44 million -3.5%14.9%7.3 $32.31 3/15/20249,350,000 shares $285.46 million +7.7%15.3%7.1 $30.53 2/29/20248,680,000 shares $307.01 million -3.7%14.3%6.1 $35.37 2/15/20249,010,000 shares $340.58 million +8.4%14.8%6 $37.80 1/31/20248,310,000 shares $302.57 million +3.4%13.7%5.5 $36.41 1/15/20248,040,000 shares $340.57 million +7.8%13.3%5.1 $42.36 12/31/20237,460,000 shares $314.29 million -2.1%12.3%4.8 $42.13 12/15/20237,620,000 shares $325.68 million +10.6%12.6%3.1 $42.74 11/30/20236,890,000 shares $269.61 million -2.4%11.4%3.1 $39.13 11/15/20237,060,000 shares $241.73 million +5.5%11.6%3.3 $34.24 10/31/20236,690,000 shares $221.10 million -0.3%14.3%3 $33.05The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 10/15/20236,710,000 shares $251.02 million -8.0%14.3%3.2 $37.41 9/30/20237,290,000 shares $279.86 million +42.1%15.5%3.5 $38.39 9/15/20235,130,000 shares $111.89 million +4.7%9.7%4.6 $21.81 8/31/20234,900,000 shares $111.28 million +28.6%9.3%4.3 $22.71 8/15/20233,810,000 shares $78.18 million +2.7%7.3%3.4 $20.52 7/31/20233,710,000 shares $84.70 million +3.6%7.2%3.4 $22.83 7/15/20233,580,000 shares $74.25 million -2.7%6.9%3.2 $20.74 6/30/20233,680,000 shares $69.81 million +7.6%7.1%3.5 $18.97 6/15/20233,420,000 shares $72.26 million -0.3%6.6%3.2 $21.13 5/31/20233,430,000 shares $72.06 million -20.4%6.7%3.4 $21.01 5/15/20234,310,000 shares $79.35 million -4.9%8.4%4.6 $18.41 4/30/20234,530,000 shares $73.11 million -3.6%8.8%5.2 $16.14 4/15/20234,700,000 shares $67.07 million -3.5%9.2%5.5 $14.27 3/31/20234,870,000 shares $75.53 million +21.8%9.4%5.2 $15.51 3/15/20234,000,000 shares $61.64 million +16.6%7.6%3.9 $15.41 2/28/20233,430,000 shares $59.92 million +19.9%6.6%3.2 $17.47 2/15/20232,860,000 shares $51.85 million +23.3%5.5%2.6 $18.13 1/31/20232,320,000 shares $41.23 million -4.5%4.4%2 $17.77 1/15/20232,430,000 shares $45.20 million -32.5%4.7%2.1 $18.60 12/30/20223,600,000 shares $63.90 million +27.2%7.0%3.2 $17.75 12/15/20222,830,000 shares $43.04 million +8.0%5.5%2 $15.21 11/30/20222,620,000 shares $34.35 million -9.7%5.1%2.1 $13.11 11/15/20222,900,000 shares $38.54 million +7.8%5.6%2.6 $13.29 10/31/20222,690,000 shares $30.13 million -11.2%6.2%2.5 $11.20 10/15/20223,030,000 shares $27.85 million +6.3%7.0%3.2 $9.19 9/30/20222,850,000 shares $15.90 million +7.1%6.5%3.4 $5.58 9/15/20222,660,000 shares $13.51 million +56.5%6.7%7.8 $5.08 8/31/20221,700,000 shares $8.76 million +9.0%4.3%5 $5.15 8/15/20221,560,000 shares $8.05 million -4.9%3.8%4.6 $5.16 7/31/20221,640,000 shares $6.76 million -9.9%4.0%5.2 $4.12 7/15/20221,820,000 shares $7.90 million +1.1%4.4%5.4 $4.34 6/30/20221,800,000 shares $7.02 million -13.0%4.4%4.9 $3.90 6/15/20222,070,000 shares $7.14 million -10.4%5.0%5 $3.45 5/31/20222,310,000 shares $9.79 million +0.9%5.6%4.5 $4.24 5/15/20222,290,000 shares $9.25 million -8.8%5.5%4.3 $4.04 4/30/20222,510,000 shares $11.57 million +3.3%6.1%4.3 $4.61 4/15/20222,430,000 shares $12.15 million +5.2%5.9%3.9 $5.00 3/31/20222,310,000 shares $12.73 million -17.5%5.6%3.3 $5.51 3/15/20222,800,000 shares $14.76 million -3.1%6.8%4.1 $5.27 2/28/20222,890,000 shares $16.13 million +8.2%7.1%4.2 $5.58 2/15/20222,670,000 shares $15.27 million +1.1%6.6%3.7 $5.72 1/31/20222,640,000 shares $18.45 million +2.7%6.5%3.7 $6.99 1/15/20222,570,000 shares $20.20 million +11.3%N/A0 $7.86 12/31/20212,310,000 shares $19.68 million -28.3%5.7%3.6 $8.52 12/15/20213,220,000 shares $25.34 million -5.6%8.0%5.4 $7.87 11/30/20213,410,000 shares $26.26 million +3.0%8.4%6.7 $7.70 11/15/20213,310,000 shares $27.08 million -10.8%8.2%6.1 $8.18 10/29/20213,710,000 shares $29.83 million +4.2%9.2%5.9 $8.04 10/15/20213,560,000 shares $31.04 million -1.9%8.8%3.6 $8.72 9/30/20213,630,000 shares $31.54 million -15.2%9.0%3.5 $8.69The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/15/20214,280,000 shares $36.51 million -5.5%10.6%4.1 $8.53 8/31/20214,530,000 shares $39.23 million -11.5%11.2%4.2 $8.66 8/13/20215,120,000 shares $40.35 million +9.6%18.5%3.4 $7.88 7/30/20214,670,000 shares $48.85 million +2.2%20.5%3.2 $10.46 7/15/20214,570,000 shares $46.11 million -19.8%11.5%4 $10.09 6/30/20215,700,000 shares $60.25 million +6.0%14.3%5.2 $10.57 6/15/20215,380,000 shares $57.89 million -2.9%13.5%4.8 $10.76 5/28/20215,540,000 shares $83.99 million -13.7%13.9%4.8 $15.16 5/14/20216,420,000 shares $93.80 million +11.7%16.2%5.9 $14.61 4/30/20215,750,000 shares $93.73 million No Change14.2%4.3 $16.30 4/15/20215,750,000 shares $91.51 million -10.9%14.2%3.7 $15.92 3/31/20216,450,000 shares $96.75 million +41.1%15.9%4.1 $15.00 3/15/20214,570,000 shares $77.64 million +20.3%11.1%2.9 $16.99 2/26/20213,800,000 shares $60.57 million +12.4%9.2%2.7 $15.94 2/12/20213,380,000 shares $79.40 million +34.7%8.2%3.3 $23.49 1/29/20212,510,000 shares $98.44 million -1.6%6.2%3.3 $39.22 1/15/20212,550,000 shares $113.50 million -7.3%6.3%6.1 $44.51 12/31/20202,750,000 shares $135.66 million +118.3%6.8%6.7 $49.33 12/15/20201,260,000 shares $61.66 million -8.7%3.1%3 $48.94 11/30/20201,380,000 shares $68.77 million -28.1%3.4%3.2 $49.83 11/15/20201,920,000 shares $97.29 million -18.3%4.8%3.7 $50.67 10/30/20202,350,000 shares $100.93 million -7.1%7.7%4.4 $42.95 10/15/20202,530,000 shares $105.70 million +6.8%6.9%5 $41.78 9/30/20202,370,000 shares $83.40 million +52.9%6.4%5 $35.19 9/15/20201,550,000 shares $59.95 million +31.4%4.5%3 $38.68 8/31/20201,180,000 shares $40.07 million +26.9%3.5%2.2 $33.96 8/14/2020929,700 shares $25.40 million -13.9%2.7%2 $27.32 7/31/20201,080,000 shares $24.42 million -8.5%3.1%2.5 $22.61 7/15/20201,180,000 shares $28.54 million -11.9%3.4%2.8 $24.19 IMVT Short Interest - Frequently Asked Questions What is Immunovant's current short interest? Short interest is the volume of Immunovant shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 19,920,000 shares of IMVT short. 29.05% of Immunovant's shares are currently sold short. Learn More on Immunovant's current short interest. What is a good short interest ratio for Immunovant? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMVT shares currently have a short interest ratio of 13.0. Learn More on Immunovant's short interest ratio. Which institutional investors are shorting Immunovant? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immunovant: Jane Street Group LLC, Caption Management LLC, and HAP Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immunovant? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 29.05% of Immunovant's floating shares are currently sold short. Is Immunovant's short interest increasing or decreasing? Immunovant saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 19,920,000 shares, a decrease of 8.1% from the previous total of 21,680,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immunovant's float size? Immunovant currently has issued a total of 170,920,000 shares. Some of Immunovant's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunovant currently has a public float of 68,570,000 shares. How does Immunovant's short interest compare to its competitors? 29.05% of Immunovant's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Immunovant: Soleno Therapeutics, Inc. (9.72%), Qiagen N.V. (2.63%), Moderna, Inc. (18.56%), Ascendis Pharma A/S (7.33%), Viatris Inc. (3.74%), Blueprint Medicines Corporation (5.06%), BridgeBio Pharma, Inc. (13.60%), Verona Pharma PLC American Depositary Share (10.39%), Roivant Sciences Ltd. (10.75%), Elanco Animal Health Incorporated (4.93%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Immunovant stock? Short selling IMVT is an investing strategy that aims to generate trading profit from Immunovant as its price is falling. IMVT shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunovant? A short squeeze for Immunovant occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMVT, which in turn drives the price of the stock up even further. How often is Immunovant's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMVT, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Soleno Therapeutics Short Interest Data Qiagen Short Interest Data Moderna Short Interest Data Ascendis Pharma A/S Short Interest Data Viatris Short Interest Data Blueprint Medicines Short Interest Data BridgeBio Pharma Short Interest Data Verona Pharma PLC American Depositary Share Short Interest Data Roivant Sciences Short Interest Data Elanco Animal Health Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMVT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
